Thus, our observations show simultaneous β1 integrin/JNK targeting in combination with RCT to be superior to RCT, AIIB2 and JNKi alone in terms of tumor growth delay and overall survival in an orthotopic GBM model. The gene discussed is MAPK8; the disease is glioblastoma.